Improvements in health-related quality of life in patients with severe sickle cell disease after exagamglogene autotemcel
Akshay Sharma(St. Jude Children's Research Hospital), Haydar Frangoul(Children’s Hospital at TriStar Centennial), Nanxin Li(Genomics Institute of the Novartis Research Foundation), Franco Locatelli(Bambino Gesù Children's Hospital), Lyndsay Molinari, Monica Bhatia(Columbia University Irving Medical Center), Wally R. Smith(Virginia Commonwealth University), Jaime Rubin(Vertex Pharmaceuticals (United States)), Kevin H.M. Kuo(University Health Network), Robert I. Liem(Lurie Children's Hospital), Michael J. Eckrich(Levine Children's Hospital), Tina Liu, Suzan Imren(Fred Hutch Cancer Center), Stephan A. Grupp(Children's Hospital of Philadelphia), William Hobbs(Vertex Pharmaceuticals (United States)), Laurence Dedeken(Université Libre de Bruxelles), Markus Y. Mapara(Sheba Medical Center), Puja Kohli(Brigham and Women's Hospital), Donna A. Wall(University of Manitoba)
Cited by 4
Related Papers
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
|New England Journal of Medicine|2020|1.8k